Address
Sussex innovation Centre
Science Park Square
Falmer, Brighton
East Sussex
BN1 9SB, United Kingdom
Contact
William Love+4401273704440
wl@destinypharma.com
Website
Clinical stage antimicrobials that address AMR
Product or Service Two phase 3 ready antibacterial assets which prevent infection
Both products address AMR and spare antibiotic use
Technology:
Microorganisms:
Application:
Development stage:
- Infection prevention
- Antimicrobial compound/strategy
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- GII
- SSI
- UTI
- STI
- BSI
- RTI
- SSTI
- CNSI
- IAI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
National territory and global licensing rights deals will be considered for phase 3 ready assets. Partner capable of supporting product development through phase 3 to approval and marketing within the relevant territory.
Clinical stage, UK based, biotechnology company focused on novel antimicrobials that prevent and treat infection
Preclinical: SPOR-COV immune boosting biotherapeutic for the prevention of viral respiratory infection, COVID-19. XF 73 dermal, treatment of bacterial skin infections. XF drug based bacterial biofilm active approaches.
